{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T22:29:33Z","timestamp":1784845773809,"version":"3.55.0"},"update-to":[{"DOI":"10.1002\/14651858.cd013247","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000}}],"reference-count":279,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013247.pub2","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T11:12:15Z","timestamp":1652872335000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Ocrelizumab for multiple sclerosis"],"prefix":"10.1002","volume":"2022","author":[{"given":"Mengbing","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Neurology; Second Affiliated Hospital of Guangxi Medical University; Nanning China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology; Second Affiliated Hospital of Guangxi Medical University; Nanning China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurology; Second Affiliated Hospital of Guangxi Medical University; Nanning China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiefeng","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Neurology; Second Affiliated Hospital of Guangxi Medical University; Nanning China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengliang","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Neurology; Second Affiliated Hospital of Guangxi Medical University; Nanning China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"10.1002\/14651858.CD013247.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"102279","DOI":"10.1016\/j.msard.2020.102279","article-title":"The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis","volume":"44","author":"Baker","year":"2020","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"2","key":"10.1002\/14651858.CD013247.pub2-BIB0002|cit2","first-page":"NP14","article-title":"Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis","volume":"24","author":"Barkhof","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"16 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0003|cit3","article-title":"Rapid onset of ocrelizumab suppression of brain MRI activity in relapsing-remitting multiple sclerosis","volume":"88","author":"Barkhof","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD013247.pub2-BIB0004|cit4","article-title":"Long-term efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS): week 96 results of a phase II, randomized, multicenter trial","volume":"78","author":"Hauser","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD013247.pub2-BIB0005|cit5","article-title":"Week 144 results of a phase II, randomized, multicenter trial assessing the safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis","volume":"80","author":"Hauser","year":"2013","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD013247.pub2-BIB0006|cit6","first-page":"1875","article-title":"Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial","volume":"18","author":"Kappos","year":"2012","journal-title":"Multiple Sclerosis"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0007|cit7","first-page":"S33","article-title":"Efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis: week 96 results of a phase II, randomised, multicentre trial","volume":"16","author":"Kappos","year":"2010","journal-title":"Multiple Sclerosis"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0008|cit8","first-page":"140","article-title":"Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial","volume":"18","author":"Kappos","year":"2012","journal-title":"Multiple Sclerosis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0009|cit9","first-page":"S65","article-title":"Long-term safety results from a phase II, randomised, multicentre trial with ocrelizumab in relapsing-remitting multiple sclerosis","volume":"259","author":"Kappos","year":"2012","journal-title":"Journal of Neurology"},{"issue":"9805","key":"10.1002\/14651858.CD013247.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet"},{"issue":"4 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0011|cit11","first-page":"446","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: brain volume results of a phase II randomised placebo-controlled multicentre trial","volume":"18","author":"Zhao","year":"2012","journal-title":"Multiple Sclerosis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0012|cit12","first-page":"120","article-title":"Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I\/OPERA II and ORATORIO","volume":"28","author":"Arnold","year":"2021","journal-title":"European Journal of Neurology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0013|cit13","article-title":"Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis","volume":"90","author":"Arnold","year":"2018","journal-title":"Neurology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0014|cit14","first-page":"8","article-title":"Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the OLE of OPERA I\/II and ORATORIO","volume":"26","author":"Arnold","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013247.pub2-BIB0015|cit15","first-page":"514","article-title":"Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies","volume":"22","author":"Arnold","year":"2016","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD013247.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.msard.2018.10.104","article-title":"Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis","volume":"26","author":"Arnold","year":"2018","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0017|cit17","first-page":"284","article-title":"Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis","volume":"24","author":"Arnold","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0018|cit18","first-page":"56","article-title":"Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies","volume":"23","author":"Balcer","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0019|cit19","first-page":"16","article-title":"Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis","volume":"24","author":"Balcer","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"19","key":"10.1002\/14651858.CD013247.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"e1778","DOI":"10.1212\/WNL.0000000000008189","article-title":"Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis","volume":"93","author":"Barkhof","year":"2019","journal-title":"Neurology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0021|cit21","article-title":"Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis","volume":"94","author":"Bar-Or","year":"2020","journal-title":"Neurology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0022|cit22","first-page":"17","article-title":"Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab","volume":"26","author":"Bar-Or","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0023|cit23","first-page":"178","article-title":"Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS","volume":"26","author":"Bar-Or","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0024|cit24","first-page":"177","article-title":"Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity","volume":"26","author":"Bar-Or","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0025|cit25","article-title":"Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials","volume":"94","author":"Bar-Or","year":"2020","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0026|cit26","first-page":"197","article-title":"Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis","volume":"27","author":"Bar-Or","year":"2020","journal-title":"European Journal of Neurology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013247.pub2-BIB0027|cit27","first-page":"322","article-title":"Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials","volume":"25","author":"Brochet","year":"2018","journal-title":"European Journal of Neurology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0028|cit28","article-title":"Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials","volume":"90","author":"Cohan","year":"2018","journal-title":"Neurology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0029|cit29","first-page":"320","article-title":"Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon \u03b2-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies","volume":"24","author":"Cree","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1002\/14651858.CD013247.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"103010","DOI":"10.1016\/j.msard.2021.103010","article-title":"Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies","volume":"52","author":"Cree","year":"2021","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"7","key":"10.1002\/14651858.CD013247.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"A435","DOI":"10.1016\/j.jval.2016.09.514","article-title":"EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS)","volume":"19","author":"Daigl","year":"2016","journal-title":"Value in Health"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD013247.pub2-BIB0032|cit32","first-page":"735","article-title":"Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies","volume":"146","author":"Derfuss","year":"2016","journal-title":"Swiss Medical Weekly"},{"issue":"4","key":"10.1002\/14651858.CD013247.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/j.clinph.2019.12.042","article-title":"Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions","volume":"131","author":"Derfuss","year":"2020","journal-title":"Clinical Neurophysiology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013247.pub2-BIB0034|cit34","first-page":"20","article-title":"Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions","volume":"25","author":"Derfuss","year":"2019","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013247.pub2-BIB0035|cit35","first-page":"351","article-title":"Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis","volume":"22","author":"De S\u00e8ze","year":"2016","journal-title":"Multiple Sclerosis"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0036|cit36","first-page":"878","article-title":"Infusion-related reactions with ocrelizumab in phase III studies","volume":"23","author":"De S\u00e8ze","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013247.pub2-BIB0037|cit37","first-page":"837","article-title":"NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies","volume":"22","author":"Giovannoni","year":"2016","journal-title":"Multiple Sclerosis"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0038|cit38","article-title":"Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis","volume":"94","author":"Giovannoni","year":"2020","journal-title":"Neurology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0039|cit39","first-page":"222","article-title":"Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS","volume":"26","author":"Giovannoni","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"4","key":"10.1002\/14651858.CD013247.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/ene.14823","article-title":"Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials","volume":"29","author":"Giovannoni","year":"2022","journal-title":"European Journal of Neurology"},{"issue":"Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jns.2019.10.1401","article-title":"Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis","volume":"405","author":"Giovannoni","year":"2019","journal-title":"Journal of the Neurological Sciences"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013247.pub2-BIB0042|cit42","first-page":"537","article-title":"Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis","volume":"25","author":"Giovannoni","year":"2019","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD013247.pub2-BIB0043|cit43","first-page":"72S","article-title":"Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies","volume":"146","author":"Gobbi","year":"2016","journal-title":"Swiss Medical Weekly"},{"key":"10.1002\/14651858.CD013247.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"101593","DOI":"10.1016\/j.msard.2019.11.068","article-title":"Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis","volume":"37","author":"Gouider","year":"2020","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013247.pub2-BIB0045|cit45","first-page":"29","article-title":"Effect of ocrelizumab versus interferon \u03b2-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis","volume":"25","author":"Green","year":"2019","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013247.pub2-BIB0046|cit46","first-page":"658","article-title":"Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis","volume":"22","author":"Arnold","year":"2016","journal-title":"Multiple Sclerosis"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0047|cit47","article-title":"Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis","volume":"90","author":"Hauser","year":"2018","journal-title":"Neurology"},{"issue":"Suppl 14","key":"10.1002\/14651858.CD013247.pub2-BIB0048|cit48","article-title":"Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis","volume":"84","author":"Hauser","year":"2015","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0049|cit49","first-page":"751","article-title":"Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis","volume":"22","author":"Hauser","year":"2015","journal-title":"European Journal of Neurology"},{"issue":"16 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0050|cit50","article-title":"Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis","volume":"88","author":"Hauser","year":"2017","journal-title":"Neurology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0051|cit51","first-page":"44","article-title":"B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis","volume":"27","author":"Hauser","year":"2021","journal-title":"Multiple Sclerosis Journal"},{"issue":"3","key":"10.1002\/14651858.CD013247.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013247.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.msard.2018.10.105","article-title":"Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis","volume":"26","author":"Hauser","year":"2018","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0054|cit54","first-page":"285","article-title":"Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis","volume":"24","author":"Hauser","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"11 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0055|cit55","first-page":"61","article-title":"Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies","volume":"23","author":"Hauser","year":"2015","journal-title":"Multiple Sclerosis"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0056|cit56","first-page":"46","article-title":"Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions","volume":"24","author":"Hauser","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"8","key":"10.1002\/14651858.CD013247.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1016\/j.clinph.2019.04.703","article-title":"Long-term reduction of relapse rate and confirmed disability progression after 5\u202fyears of ocrelizumab treatment in patients with relapsing multiple sclerosis","volume":"130","author":"Hauser","year":"2019","journal-title":"Clinical Neurophysiology"},{"issue":"13","key":"10.1002\/14651858.CD013247.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"e1854","DOI":"10.1212\/WNL.0000000000010376","article-title":"Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension","volume":"95","author":"Hauser","year":"2020","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD013247.pub2-BIB0059|cit59","first-page":"NP13","article-title":"Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis","volume":"24","author":"Hauser","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0060|cit60","first-page":"45","article-title":"Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS","volume":"26","author":"Hauser","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0061|cit61","first-page":"496","article-title":"Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis","volume":"26","author":"Hauser","year":"2019","journal-title":"European Journal of Neurology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0062|cit62","article-title":"Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis","volume":"92","author":"Hauser","year":"2019","journal-title":"Neurology"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0063|cit63","first-page":"331","article-title":"Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies","volume":"23","author":"Hauser","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0064|cit64","first-page":"324","article-title":"Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis","volume":"23","author":"Hauser","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"2","key":"10.1002\/14651858.CD013247.pub2-BIB0065|cit65","first-page":"NP13","article-title":"Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis","volume":"24","author":"Hauser","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013247.pub2-BIB0066|cit66","first-page":"334","article-title":"Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis","volume":"25","author":"Hauser","year":"2018","journal-title":"European Journal of Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0067|cit67","first-page":"497","article-title":"Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials","volume":"24","author":"Havrdova","year":"2017","journal-title":"European Journal of Neurology"},{"issue":"16 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0068|cit68","article-title":"No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies","volume":"88","author":"Havrdova","year":"2017","journal-title":"Neurology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0069|cit69","article-title":"Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment","volume":"94","author":"Jia","year":"2020","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0070|cit70","first-page":"572","article-title":"Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies","volume":"24","author":"Kappos","year":"2017","journal-title":"European Journal of Neurology"},{"issue":"16 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0071|cit71","article-title":"Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis","volume":"88","author":"Kappos","year":"2017","journal-title":"Neurology"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD013247.pub2-BIB0072|cit72","first-page":"46S","article-title":"Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies","volume":"146","author":"Kappos","year":"2016","journal-title":"Swiss Medical Weekly"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0073|cit73","first-page":"309","article-title":"Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis","volume":"23","author":"Kappos","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"9","key":"10.1002\/14651858.CD013247.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0075|cit75","first-page":"256","article-title":"Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies","volume":"24","author":"Kappos","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0076|cit76","first-page":"120","article-title":"Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning","volume":"26","author":"Krishnan","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0077|cit77","first-page":"120","article-title":"Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning","volume":"26","author":"Krishnan","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013247.pub2-BIB0078|cit78","first-page":"200","article-title":"Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS","volume":"23","author":"Kuhelj","year":"2016","journal-title":"European Journal of Neurology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013247.pub2-BIB0079|cit79","first-page":"402","article-title":"Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) \u03b2-1a-controlled studies","volume":"23","author":"Lublin","year":"2016","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD013247.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.msard.2019.01.044","article-title":"Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies","volume":"30","author":"Mayer","year":"2019","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"16 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0081|cit81","article-title":"Preliminary results of the OPERA I and OPERA II open-label extension study","volume":"88","author":"Naismith","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD013247.pub2-BIB0082|cit82","first-page":"NP8","article-title":"Preliminary results of the OPERA I and OPERA II open label extension study","volume":"24","author":"Naismith","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0083|cit83","first-page":"332","article-title":"Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies","volume":"23","author":"Papeix","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"9","key":"10.1002\/14651858.CD013247.pub2-BIB0084|cit84","first-page":"NP66","article-title":"Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]","volume":"26","author":"Parratt","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0085|cit85","first-page":"31","article-title":"Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis","volume":"23","author":"Rammohan","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013247.pub2-BIB0086|cit86","first-page":"202","article-title":"Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) \u03b2-1a controlled OPERA I and OPERA II studies","volume":"23","author":"Selmaj","year":"2016","journal-title":"European Journal of Neurology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0087|cit87","first-page":"411","article-title":"Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry","volume":"26","author":"Song","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013247.pub2-BIB0088|cit88","first-page":"58","article-title":"Ocrelizumab no evidence of disease activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies","volume":"23","author":"Traboulsee","year":"2016","journal-title":"European Journal of Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0089|cit89","first-page":"18","article-title":"NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies","volume":"23","author":"Traboulsee","year":"2017","journal-title":"Multiple Sclerosis"},{"issue":"16 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0090|cit90","article-title":"Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies","volume":"88","author":"Traboulsee","year":"2017","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD013247.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1007\/s00415-019-09248-6","article-title":"Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis","volume":"266","author":"Turner","year":"2019","journal-title":"Journal of Neurology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013247.pub2-BIB0092|cit92","first-page":"534","article-title":"Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II","volume":"25","author":"Turner","year":"2018","journal-title":"European Journal of Neurology"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0093|cit93","first-page":"333","article-title":"Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies","volume":"23","author":"Turner","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0094|cit94","first-page":"312","article-title":"Ocrelizumab does not modulate peripheral T cell functionality or prevalence in a small subset of relapsing MS patients enrolled in OPERA I, a phase III double-blind double-dummy interferon beta-1a-controlled study","volume":"23","author":"Shon Nguyen","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0095|cit95","article-title":"Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis","volume":"90","author":"Wolinsky","year":"2018","journal-title":"Neurology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013247.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"S330","DOI":"10.1016\/j.jval.2018.09.1974","article-title":"An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability","volume":"21","author":"Xu","year":"2018","journal-title":"Value in Health"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0097|cit97","first-page":"120","article-title":"Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I\/OPERA II and ORATORIO","volume":"28","author":"Arnold","year":"2021","journal-title":"European Journal of Neurology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0098|cit98","article-title":"Brain MRI activity and atrophy measures in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis","volume":"90","author":"Arnold","year":"2018","journal-title":"Neurology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0099|cit99","first-page":"8","article-title":"Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I\/II and ORATORIO","volume":"26","author":"Arnold","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013247.pub2-BIB0100|cit100","first-page":"514","article-title":"Effect of ocrelizumab on magnetic resonance imaging markers of neurodegeneration in patients with relapsing multiple sclerosis: analysis of the Phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies","volume":"22","author":"Arnold","year":"2016","journal-title":"Multiple Sclerosis"},{"key":"10.1002\/14651858.CD013247.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.msard.2018.10.104","article-title":"Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis","volume":"26","author":"Arnold","year":"2018","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0102|cit102","first-page":"284","article-title":"Long-term reduction in brain MRI disease activity and atrophy after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis","volume":"24","author":"Arnold","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0103|cit103","first-page":"56","article-title":"Effect of ocrelizumab vs that of interferon beta-1a on visual outcomes in patients with relapsing multiple sclerosis in the OPERA studies","volume":"23","author":"Balcer","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0104|cit104","first-page":"16","article-title":"Effect of ocrelizumab on visual outcomes in patients with baseline visual impairment in the opera studies in relapsing multiple sclerosis","volume":"24","author":"Balcer","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"19","key":"10.1002\/14651858.CD013247.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"e1778","DOI":"10.1212\/WNL.0000000000008189","article-title":"Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis","volume":"93","author":"Barkhof","year":"2019","journal-title":"Neurology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0106|cit106","article-title":"Serum Ig levels and risk of serious infections by baseline Ig quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis","volume":"94","author":"Bar-Or","year":"2020","journal-title":"Neurology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0107|cit107","first-page":"178","article-title":"Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS","volume":"26","author":"Bar-Or","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0108|cit108","first-page":"177","article-title":"Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity","volume":"26","author":"Bar-Or","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0109|cit109","first-page":"197","article-title":"Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis","volume":"27","author":"Bar-Or","year":"2020","journal-title":"European Journal of Neurology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013247.pub2-BIB0110|cit110","first-page":"322","article-title":"Effect of ocrelizumab on relapse rate, and disability progression and improvement in relapsing multiple sclerosis patients in the open-label extension of the pooled OPERA trials","volume":"25","author":"Brochet","year":"2018","journal-title":"European Journal of Neurology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0111|cit111","article-title":"Time to cognitive worsening in patients with relapsing multiple sclerosis in ocrelizumab phase III trials","volume":"90","author":"Cohan","year":"2018","journal-title":"Neurology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0112|cit112","first-page":"320","article-title":"Subgroup analysis to evaluate the efficacy of ocrelizumab versus interferon \u03b2-1a in African-descended patients with relapsing multiple sclerosis in the OPERA I and OPERA II studies","volume":"24","author":"Cree","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1002\/14651858.CD013247.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"103010","DOI":"10.1016\/j.msard.2021.103010","article-title":"Efficacy and safety of ocrelizumab vs interferon beta-1a in participants of African descent with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies","volume":"52","author":"Cree","year":"2021","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"7","key":"10.1002\/14651858.CD013247.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"A435","DOI":"10.1016\/j.jval.2016.09.514","article-title":"EDSS state and health utility measured by EQ5D in relapsing-remitting multiple sclerosis (RRMS)","volume":"19","author":"Daigl","year":"2016","journal-title":"Value in Health"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD013247.pub2-BIB0115|cit115","first-page":"735","article-title":"Efficacy of ocrelizumab in patients with relapsing multiple sclerosis: pooled analysis of two identical phase III, double-blind, double-dummy, interferon beta-1a-controlled studies","volume":"146","author":"Derfuss","year":"2016","journal-title":"Swiss Medical Weekly"},{"issue":"4","key":"10.1002\/14651858.CD013247.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/j.clinph.2019.12.042","article-title":"Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions","volume":"131","author":"Derfuss","year":"2020","journal-title":"Clinical Neurophysiology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013247.pub2-BIB0117|cit117","first-page":"20","article-title":"Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions","volume":"25","author":"Derfuss","year":"2019","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013247.pub2-BIB0118|cit118","first-page":"351","article-title":"Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis","volume":"22","author":"De S\u00e8ze","year":"2016","journal-title":"Multiple Sclerosis"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0119|cit119","first-page":"878","article-title":"Infusion-related reactions with ocrelizumab in phase III studies","volume":"23","author":"De S\u00e8ze","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013247.pub2-BIB0120|cit120","first-page":"837","article-title":"NEDA epoch analysis of patients with relapsing multiple sclerosis treated with ocrelizumab: results from OPERA I and OPERA II, phase III studies","volume":"23","author":"Giovannoni","year":"2016","journal-title":"Multiple Sclerosis"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0121|cit121","article-title":"Long-term reduction of confirmed disability progression and time to walking aid after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis","volume":"94","author":"Giovannoni","year":"2020","journal-title":"Neurology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0122|cit122","first-page":"222","article-title":"Long-term reduction of relapse rate and 48-week confirmed disability progression after 6.5 years of ocrelizumab treatment in patients with RMS","volume":"26","author":"Giovannoni","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"4","key":"10.1002\/14651858.CD013247.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/ene.14823","article-title":"Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: data from the OPERA I and OPERA II trials","volume":"29","author":"Giovannoni","year":"2022","journal-title":"European Journal of Neurology"},{"issue":"Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jns.2019.10.1401","article-title":"Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis","volume":"405","author":"Giovannoni","year":"2019","journal-title":"Journal of the Neurological Sciences"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013247.pub2-BIB0125|cit125","first-page":"537","article-title":"Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis","volume":"25","author":"Giovannoni","year":"2019","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD013247.pub2-BIB0126|cit126","first-page":"72S","article-title":"Effect of ocrelizumab on MRI inflammatory and neurodegenerative markers of disease in patients with relapsing multiple sclerosis: analysis of the phase III, double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies","volume":"146","author":"Gobbi","year":"2016","journal-title":"Swiss Medical Weekly"},{"key":"10.1002\/14651858.CD013247.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"101593","DOI":"10.1016\/j.msard.2019.11.068","article-title":"Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing multiple sclerosis","volume":"37","author":"Gouider","year":"2020","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013247.pub2-BIB0128|cit128","first-page":"29","article-title":"Effect of ocrelizumab versus interferon \u03b2-1a on retinal thinning and association with brain volume loss in the OPERA I and OPERA II Phase III trials in relapsing multiple sclerosis","volume":"25","author":"Green","year":"2019","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013247.pub2-BIB0129|cit129","first-page":"658","article-title":"Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis","volume":"22","author":"Arnold","year":"2016","journal-title":"Multiple Sclerosis"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0130|cit130","article-title":"Annualized relapse rate and confirmed disability progression in patients receiving continuous ocrelizumab or switching from interferon beta-1a to ocrelizumab therapy in the open-label extension period of the phase III trials of ocrelizumab in patients with relapsing multiple sclerosis","volume":"90","author":"Hauser","year":"2018","journal-title":"Neurology"},{"issue":"Suppl 14","key":"10.1002\/14651858.CD013247.pub2-BIB0131|cit131","article-title":"Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis","volume":"84","author":"Hauser","year":"2015","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0132|cit132","first-page":"751","article-title":"Baseline demographics and disease characteristics from OPERA I and II, two phase III trials evaluating ocrelizumab in patients with relapsing multiple sclerosis","volume":"22","author":"Hauser","year":"2015","journal-title":"European Journal of Neurology"},{"issue":"16 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0133|cit133","article-title":"Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis","volume":"88","author":"Hauser","year":"2017","journal-title":"Neurology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0134|cit134","first-page":"44","article-title":"B-cell subset depletion following ocrelizumab treatment in patients with relapsing multiple sclerosis","volume":"27","author":"Hauser","year":"2021","journal-title":"Multiple Sclerosis Journal"},{"issue":"3","key":"10.1002\/14651858.CD013247.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013247.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.msard.2018.10.105","article-title":"Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis","volume":"26","author":"Hauser","year":"2018","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0137|cit137","first-page":"285","article-title":"Long-term reduction of relapse rate and confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis","volume":"24","author":"Hauser","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"11 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0138|cit138","first-page":"61","article-title":"Efficacy and safety of ocrelizumab in relapsing multiple sclerosis-results of the interferon-beta-1a-controlled, double blind, Phase III OPERA I and II studies","volume":"23","author":"Hauser","year":"2015","journal-title":"Multiple Sclerosis"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0139|cit139","first-page":"46","article-title":"Ocrelizumab safety in patients with multiple sclerosis: Updated analyses with a focus on infusion-related reactions","volume":"24","author":"Hauser","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"8","key":"10.1002\/14651858.CD013247.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1016\/j.clinph.2019.04.703","article-title":"Long-term reduction of relapse rate and confirmed disability progression after 5\u202fyears of ocrelizumab treatment in patients with relapsing multiple sclerosis","volume":"130","author":"Hauser","year":"2019","journal-title":"Clinical Neurophysiology"},{"issue":"13","key":"10.1002\/14651858.CD013247.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"e1854","DOI":"10.1212\/WNL.0000000000010376","article-title":"Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension","volume":"95","author":"Hauser","year":"2020","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD013247.pub2-BIB0142|cit142","first-page":"NP13","article-title":"Rapidity of onset of ocrelizumab clinical efficacy in relapsing multiple sclerosis","volume":"24","author":"Hauser","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0143|cit143","first-page":"45","article-title":"Long-term reduction of relapse rate and confirmed disability progression after 6 years of ocrelizumab treatment in patients with relapsing MS","volume":"26","author":"Hauser","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0144|cit144","first-page":"496","article-title":"Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis","volume":"26","author":"Hauser","year":"2019","journal-title":"European Journal of Neurology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0145|cit145","article-title":"Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis","volume":"92","author":"Hauser","year":"2019","journal-title":"Neurology"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0146|cit146","first-page":"331","article-title":"Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies","volume":"23","author":"Hauser","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0147|cit147","first-page":"324","article-title":"Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis","volume":"23","author":"Hauser","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"2","key":"10.1002\/14651858.CD013247.pub2-BIB0148|cit148","first-page":"NP13","article-title":"Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis","volume":"24","author":"Hauser","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013247.pub2-BIB0149|cit149","first-page":"334","article-title":"Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis","volume":"25","author":"Hauser","year":"2018","journal-title":"European Journal of Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0150|cit150","first-page":"497","article-title":"Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with relapsing multiple sclerosis in the OPERA I and OPERA II trials","volume":"24","author":"Havrdova","year":"2017","journal-title":"European Journal of Neurology"},{"issue":"16 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0151|cit151","article-title":"No evidence of disease activity on ocrelizumab treatment in patients with early relapsing multiple sclerosis: pooled analysis of the Phase III OPERA studies","volume":"88","author":"Havrdova","year":"2017","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0152|cit152","first-page":"572","article-title":"Reduction in progression to disability milestones by ocrelizumab in patients with relapsing multiple sclerosis: an exploratory analysis of pooled OPERA I and OPERA II studies","volume":"24","author":"Kappos","year":"2017","journal-title":"European Journal of Neurology"},{"issue":"16 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0153|cit153","article-title":"Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis","volume":"88","author":"Kappos","year":"2017","journal-title":"Neurology"},{"issue":"Suppl 219","key":"10.1002\/14651858.CD013247.pub2-BIB0154|cit154","first-page":"46S","article-title":"Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in patients with relapsing multiple sclerosis: analysis of the Phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies","volume":"146","author":"Kappos","year":"2016","journal-title":"Swiss Medical Weekly"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0155|cit155","first-page":"309","article-title":"Ocrelizumab reduces disability progression independent of relapse activity in patients with relapsing multiple sclerosis","volume":"23","author":"Kappos","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"9","key":"10.1002\/14651858.CD013247.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of relapse-independent progression vs relapse-associated worsening to overall confirmed disability accumulation in typical relapsing multiple sclerosis in a pooled analysis of 2 randomized clinical trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0157|cit157","first-page":"256","article-title":"Relapse-associated worsening and progression independent of relapse activity in patients with relapsing multiple sclerosis in the Phase III OPERA I and OPERA II studies","volume":"24","author":"Kappos","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0158|cit158","first-page":"120","article-title":"Detecting treatment response on T1 gadolinium enhancing lesion burden in clinical trials of multiple sclerosis with deep learning","volume":"26","author":"Krishnan","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0159|cit159","first-page":"120","article-title":"Detecting treatment response on T2 lesion burden in multiple sclerosis clinical trials with deep learning","volume":"26","author":"Krishnan","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013247.pub2-BIB0160|cit160","first-page":"200","article-title":"Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS","volume":"23","author":"Kuhelj","year":"2016","journal-title":"European Journal of Neurology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013247.pub2-BIB0161|cit161","first-page":"402","article-title":"Effect of ocrelizumab on clinical disability in two identical Phase III, double-blind, double-dummy, interferon (IFN) \u03b2-1a-controlled studies","volume":"23","author":"Lublin","year":"2016","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD013247.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.msard.2019.01.044","article-title":"Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies","volume":"30","author":"Mayer","year":"2019","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"16 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0163|cit163","article-title":"Preliminary results of the OPERA I and OPERA II open-label extension study","volume":"88","author":"Naismith","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"10.1002\/14651858.CD013247.pub2-BIB0164|cit164","first-page":"NP8","article-title":"Preliminary results of the OPERA I and OPERA II open label extension study","volume":"24","author":"Naismith","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0165|cit165","first-page":"332","article-title":"Subgroup analyses of annualised relapse rates in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies","volume":"23","author":"Papeix","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"9","key":"10.1002\/14651858.CD013247.pub2-BIB0166|cit166","first-page":"NP66","article-title":"Long-term reduction in 48-week confirmed disability progression after 5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis [encore]","volume":"26","author":"Parratt","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0167|cit167","first-page":"31","article-title":"Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis","volume":"23","author":"Rammohan","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013247.pub2-BIB0168|cit168","first-page":"202","article-title":"Infusion-related reactions with ocrelizumab in the Phase III double-blind, double-dummy, interferon (IFN) \u03b2-1a controlled OPERA I and OPERA II studies","volume":"23","author":"Selmaj","year":"2016","journal-title":"European Journal of Neurology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0169|cit169","first-page":"411","article-title":"Ocrelizumab reduces regional brain atrophy in relapsing multiple sclerosis as assessed by longitudinal deformation based morphometry","volume":"26","author":"Song","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013247.pub2-BIB0170|cit170","first-page":"58","article-title":"Ocrelizumab No Evidence of Disease Activity (NEDA) status at 96 weeks in relapsing multiple sclerosis patients: analysis of the OPERA I and OPERA II studies","volume":"23","author":"Traboulsee","year":"2016","journal-title":"European Journal of Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0171|cit171","first-page":"18","article-title":"NEDA analysis by epoch in patients with relapsing multiple sclerosis treated with ocrelizumab: results from the OPERA I and OPERA II phase III studies","volume":"23","author":"Traboulsee","year":"2017","journal-title":"Multiple Sclerosis"},{"issue":"16 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0172|cit172","article-title":"Efficacy of ocrelizumab on brain MRI outcomes in patients with early relapsing multiple sclerosis: pooled analysis of the opera studies","volume":"88","author":"Traboulsee","year":"2017","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD013247.pub2-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1007\/s00415-019-09248-6","article-title":"Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis","volume":"266","author":"Turner","year":"2019","journal-title":"Journal of Neurology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013247.pub2-BIB0174|cit174","first-page":"534","article-title":"Subgroup analyses of NEDA re-baselined at week 24 in ocrelizumab recipients with relapsing multiple sclerosis receiving ocrelizumab in OPERA I and II","volume":"25","author":"Turner","year":"2018","journal-title":"European Journal of Neurology"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0175|cit175","first-page":"333","article-title":"Subgroup analyses of no evidence of disease activity in patients with relapsing multiple sclerosis who received ocrelizumab or interferon beta-1a in the Phase III OPERA I and OPERA II studies","volume":"23","author":"Turner","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0176|cit176","article-title":"Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis","volume":"90","author":"Wolinsky","year":"2018","journal-title":"Neurology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013247.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"S330","DOI":"10.1016\/j.jval.2018.09.1974","article-title":"An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability","volume":"21","author":"Xu","year":"2018","journal-title":"Value in Health"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0178|cit178","first-page":"120","article-title":"Effect of ocrelizumab on cerebellar atrophy in RMS and PPMS: results from OPERA I\/OPERA II and ORATORIO","volume":"28","author":"Arnold","year":"2021","journal-title":"European Journal of Neurology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0179|cit179","first-page":"8","article-title":"Reduced thalamic atrophy in patients initiating earlier versus delayed ocrelizumab therapy: results from the ole of OPERA I\/II and ORATORIO","volume":"26","author":"Arnold","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0180|cit180","first-page":"157","article-title":"Reduced rate of brain atrophy after 5 years of ocrelizumab treatment in patients with PPMS from the Phase III ORATORIO trial","volume":"26","author":"Arnold","year":"2019","journal-title":"European Journal of Neurology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0181|cit181","article-title":"Reduced rate of brain atrophy in patients with PPMS receiving ocrelizumab earlier and continuously versus those initiating ocrelizumab later: results of oratorio 5-year follow-up","volume":"92","author":"Arnold","year":"2019","journal-title":"Neurology"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0182|cit182","article-title":"Serum Ig levels and risk of serious infections by baseline IG quartile in the pivotal phase III trials and open-label extensions of ocrelizumab in multiple sclerosis","volume":"94","author":"Bar-Or","year":"2020","journal-title":"Neurology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0183|cit183","first-page":"17","article-title":"Blood neurofilament light chain levels and association with brain volume change in patients with PPMS and RMS before and under treatment with ocrelizumab","volume":"26","author":"Bar-Or","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0184|cit184","first-page":"178","article-title":"Ocrelizumab treatment induces a sustained blood NFL reduction in patients with PPMS and RMS","volume":"26","author":"Bar-Or","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0185|cit185","first-page":"177","article-title":"Ocrelizumab reduces thalamic volume loss and clinical progression in PPMS and RMS independent of baseline NFL and other measures of disease severity","volume":"26","author":"Bar-Or","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"15","key":"10.1002\/14651858.CD013247.pub2-BIB0186|cit186","article-title":"Factors associated with baseline serum neurofilament light concentrations in relapsing and primary progressive multiple sclerosis patients in the ocrelizumab OPERA 1 and ORATORIO trials","volume":"94","author":"Bar-Or","year":"2020","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0187|cit187","first-page":"197","article-title":"Blood neurofilament light levels are reduced following ocrelizumab treatment in patients with relapsing and primary progressive multiple sclerosis","volume":"27","author":"Bar-Or","year":"2020","journal-title":"European Journal of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD013247.pub2-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/ene.14824","article-title":"Risk of requiring a wheelchair in primary progressive multiple sclerosis: data from the ORATORIO trial and the MSBase registry","volume":"29","author":"Butzkueven","year":"2022","journal-title":"European Journal of Neurology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013247.pub2-BIB0189|cit189","first-page":"320","article-title":"Risk of becoming wheelchair-confined in patients with primary progressive multiple sclerosis: data from the ORATORIO trial and a long-term real-world cohort from MS base registry","volume":"26","author":"Butzkueven","year":"2018","journal-title":"European Journal of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD013247.pub2-BIB0190|cit190","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/j.clinph.2019.12.042","article-title":"Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions","volume":"131","author":"Derfuss","year":"2020","journal-title":"Clinical Neurophysiology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013247.pub2-BIB0191|cit191","first-page":"20","article-title":"Serum immunoglobulin levels and risk of serious infections in the pivotal Phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions","volume":"25","author":"Derfuss","year":"2019","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013247.pub2-BIB0192|cit192","first-page":"351","article-title":"Infusion-related reactions with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis","volume":"22","author":"De S\u00e8ze","year":"2016","journal-title":"Multiple Sclerosis"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0193|cit193","first-page":"878","article-title":"Infusion-related reactions with ocrelizumab in phase III studies","volume":"23","author":"De S\u00e8ze","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0194|cit194","first-page":"84","article-title":"Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis","volume":"23","author":"De S\u00e8ze","year":"2017","journal-title":"Multiple Sclerosis"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013247.pub2-BIB0195|cit195","first-page":"677","article-title":"Patient-reported outcomes in the phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis","volume":"22","author":"De S\u00e8ze","year":"2016","journal-title":"Multiple Sclerosis"},{"issue":"9","key":"10.1002\/14651858.CD013247.pub2-BIB0196|cit196","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1093\/brain\/awz212","article-title":"Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis","volume":"142","author":"Elliott","year":"2019","journal-title":"Brain"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0197|cit197","article-title":"Ocrelizumab may reduce tissue damage in chronic active lesions as measured by change in T1 hypo-intensity of slowly evolving lesions in patients with primary progressive multiple sclerosis","volume":"90","author":"Elliott","year":"2018","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD013247.pub2-BIB0198|cit198","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1136\/jnnp-2018-ANZAN.32","article-title":"Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis (PPMS) in the ORATORIO study (encore)","volume":"89","author":"Fox","year":"2018","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0199|cit199","first-page":"33","article-title":"Effect of ocrelizumab on severe progression of upper extremity impairment in patients with primary progressive multiple sclerosis in ORATORIO","volume":"24","author":"Fox","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0200|cit200","first-page":"658","article-title":"Effect of ocrelizumab on upper limb function in patients with primary progressive multiple sclerosis in the ORATORIO study","volume":"23","author":"Fox","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"14","key":"10.1002\/14651858.CD013247.pub2-BIB0201|cit201","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1177\/1352458518808189","article-title":"Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: findings from the phase III randomized ORATORIO trial","volume":"24","author":"Fox","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0202|cit202","first-page":"306","article-title":"Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0203|cit203","article-title":"Ocrelizumab treatment effect on upper limb function in PPMS patients with disability: subgroup results of the ORATORIO study to inform the ORATORIO-HAND study design","volume":"92","author":"Giovannoni","year":"2019","journal-title":"Neurology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013247.pub2-BIB0204|cit204","first-page":"371","article-title":"An exploratory analysis of 12-and 24-week composite confirmed disability progression in patients with primary progressive multiple sclerosis in the ORATORIO trial","volume":"22","author":"Giovannoni","year":"2016","journal-title":"Multiple Sclerosis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0205|cit205","first-page":"494","article-title":"An exploratory analysis of the risk of being restricted to wheelchair in patients with primary progressive multiple sclerosis in the ORATORIO trial","volume":"24","author":"Giovannoni","year":"2017","journal-title":"European Journal of Neurology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013247.pub2-BIB0206|cit206","first-page":"658","article-title":"Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis","volume":"22","author":"Arnold","year":"2016","journal-title":"Multiple Sclerosis"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0207|cit207","first-page":"46","article-title":"Ocrelizumab safety in patients with multiple sclerosis: updated analyses with a focus on infusion-related reactions","volume":"24","author":"Hauser","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0208|cit208","first-page":"331","article-title":"Incidence rates of malignancies in patients with multiple sclerosis in clinical trials and epidemiological studies","volume":"23","author":"Hauser","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0209|cit209","first-page":"324","article-title":"Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis","volume":"23","author":"Hauser","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"2","key":"10.1002\/14651858.CD013247.pub2-BIB0210|cit210","first-page":"NP13","article-title":"Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis","volume":"24","author":"Hauser","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013247.pub2-BIB0211|cit211","first-page":"334","article-title":"Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis","volume":"25","author":"Hauser","year":"2018","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD013247.pub2-BIB0212|cit212","first-page":"264","article-title":"Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial","volume":"26","author":"Hauser","year":"2018","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"15 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0213|cit213","article-title":"Blood neurofilament light chain levels and association with brain volume change in patients with primary progressive multiple sclerosis and relapsing multiple sclerosis before and during ocrelizumab treatment","volume":"94","author":"Jia","year":"2020","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0214|cit214","first-page":"44","article-title":"Impact of ocrelizumab on reducing more severe disability progression in primary progressive multiple sclerosis","volume":"24","author":"Kappos","year":"2017","journal-title":"European Journal of Neurology"},{"issue":"16 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0215|cit215","article-title":"Safety of ocrelizumab in multiple sclerosis: Updated analysis in patients with relapsing and primary progressive multiple sclerosis","volume":"88","author":"Kappos","year":"2017","journal-title":"Neurology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013247.pub2-BIB0216|cit216","first-page":"431","article-title":"Prespecified subgroup analyses of ocrelizumab efficacy in patients with primary progressive multiple sclerosis from the Phase III ORATORIO study","volume":"25","author":"Kappos","year":"2018","journal-title":"European Journal of Neurology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013247.pub2-BIB0217|cit217","first-page":"200","article-title":"Open-label phase III extension studies to evaluate the long-term safety and efficacy of ocrelizumab in relapsing MS and primary progressive MS","volume":"23","author":"Kuhelj","year":"2016","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD013247.pub2-BIB0218|cit218","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.msard.2019.01.044","article-title":"Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies","volume":"30","author":"Mayer","year":"2019","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"16 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0219|cit219","article-title":"The association between confirmed disability progression and patient-reported fatigue in PPMS patients in the ORATORIO study","volume":"88","author":"Miller","year":"2017","journal-title":"Neurology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013247.pub2-BIB0220|cit220","first-page":"410","article-title":"Infusion-related reactions in the Phase III double-blind, placebo-controlled ORATORIO study of ocrelizumab in primary progressive multiple sclerosis (PPMS)","volume":"23","author":"Montalban","year":"2016","journal-title":"European Journal of Neurology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013247.pub2-BIB0221|cit221","first-page":"50","article-title":"Evaluation of no evidence of progression using composite disability outcome measures, in patients with primary progressive multiple sclerosis in the ORATORIO trial","volume":"22","author":"Montalban","year":"2016","journal-title":"Multiple Sclerosis"},{"issue":"3","key":"10.1002\/14651858.CD013247.pub2-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0223|cit223","first-page":"705","article-title":"Baseline demographics and disease characteristics from ORATORIO, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis","volume":"22","author":"Montalban","year":"2015","journal-title":"European Journal of Neurology"},{"issue":"Suppl 14","key":"10.1002\/14651858.CD013247.pub2-BIB0224|cit224","article-title":"Baseline demographics and disease characteristics from oratorio, a phase III trial evaluating ocrelizumab in patients with primary progressive multiple sclerosis","volume":"84","author":"Montalban","year":"2015","journal-title":"Neurology"},{"issue":"11 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0225|cit225","first-page":"781","article-title":"Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis-results of the placebo-controlled, double-blind, Phase III ORATORIO study","volume":"23","author":"Montalban","year":"2015","journal-title":"Multiple Sclerosis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0226|cit226","first-page":"576","article-title":"Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial","volume":"24","author":"Montalban","year":"2017","journal-title":"European Journal of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD013247.pub2-BIB0227|cit227","first-page":"NP10","article-title":"Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial","volume":"24","author":"Montalban","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0228|cit228","first-page":"31","article-title":"Infections and serious infections with ocrelizumab in relapsing multiple sclerosis and primary progressive multiple sclerosis","volume":"23","author":"Rammohan","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"9","key":"10.1002\/14651858.CD013247.pub2-BIB0229|cit229","first-page":"NP37","article-title":"Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis [encore]","volume":"26","author":"Taylor","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0230|cit230","article-title":"Routine laboratory measures in the controlled-treatment period of phase III ocrelizumab trials in relapsing and progressive multiple sclerosis","volume":"90","author":"Wolinsky","year":"2018","journal-title":"Neurology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013247.pub2-BIB0231|cit231","first-page":"676","article-title":"Baseline assessment of fatigue and health-related quality of life in patients with primary progressive multiple sclerosis in the ORATORIO study","volume":"22","author":"Wolinsky","year":"2016","journal-title":"Multiple Sclerosis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0232|cit232","first-page":"17","article-title":"Evaluation of no evidence of progression (NEP) in patients with primary progressive multiple sclerosis in the ORATORIO trial","volume":"23","author":"Wolinsky","year":"2017","journal-title":"Multiple Sclerosis"},{"issue":"16 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0233|cit233","article-title":"Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial","volume":"88","author":"Wolinsky","year":"2017","journal-title":"Neurology"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0234|cit234","first-page":"234","article-title":"Sustained reduction in 48-week confirmed disability progression in patients with PPMS treated with ocrelizumab in the oratorio ole: 7-year follow-up","volume":"26","author":"Wolinsky","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"12","key":"10.1002\/14651858.CD013247.pub2-BIB0235|cit235","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1474-4422(20)30342-2","article-title":"Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial","volume":"19","author":"Wolinsky","year":"2020","journal-title":"Lancet Neurology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0236|cit236","first-page":"49","article-title":"Sustained reduction in confirmed disability progression in primary progressive MS patients treated with ocrelizumab: 6.5-study year follow-up data","volume":"26","author":"Wolinsky","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2019.10.269","article-title":"Sustained reduction in confirmed disability progression after 6.5 study-years of ocrelizumab treatment in patients with primary progressive multiple sclerosis","volume":"405","author":"Wolinsky","year":"2019","journal-title":"Journal of the Neurological Sciences"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD013247.pub2-BIB0238|cit238","first-page":"56","article-title":"Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial: 6.5-study year follow-up data","volume":"25","author":"Wolinsky","year":"2019","journal-title":"Multiple Sclerosis Journal"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD013247.pub2-BIB0239|cit239","first-page":"490","article-title":"Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial","volume":"24","author":"Wolinsky","year":"2018","journal-title":"Multiple Sclerosis Journal"},{"issue":"8","key":"10.1002\/14651858.CD013247.pub2-BIB0240|cit240","doi-asserted-by":"crossref","first-page":"e170","DOI":"10.1016\/j.clinph.2019.04.704","article-title":"Sustained reduction in confirmed disability progression in patients with primary progressive multiple sclerosis treated with ocrelizumab in the open-label extension period of the Phase III ORATORIO trial","volume":"130","author":"Wolinsky","year":"2019","journal-title":"Clinical Neurophysiology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0241|cit241","first-page":"322","article-title":"Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis","volume":"26","author":"Wolinsky","year":"2019","journal-title":"European Journal of Neurology"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0242|cit242","article-title":"Reduction in 48-week confirmed disability progression after 5.5 years of ocrelizumab treatment in patients with primary progressive multiple sclerosis","volume":"92","author":"Wolinsky","year":"2019","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD013247.pub2-BIB0243|cit243","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/ana.25313","article-title":"Evaluation of No Evidence of Progression or Active Disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial","volume":"84","author":"Wolinsky","year":"2018","journal-title":"Annals of Neurology"},{"issue":"3 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0244|cit244","first-page":"656","article-title":"Sustained and durable reduction in confirmed disability progression in patients with primary progressive multiple sclerosis receiving ocrelizumab: findings from the phase III ORATORIO study extended control period","volume":"23","author":"Wolinsky","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013247.pub2-BIB0245|cit245","doi-asserted-by":"crossref","first-page":"S330","DOI":"10.1016\/j.jval.2018.09.1974","article-title":"An exploratory analysis of efficacy of ocrelizumab for multiple sclerosis patients with increased disability","volume":"21","author":"Xu","year":"2018","journal-title":"Value in Health"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD013247.pub2-BIB0246|cit246","article-title":"Evolution of lesions that shrink or disappear into cerebrospinal fluid (atrophied T2 lesion volume) in primary-progressive multiple sclerosis: results from the Phase III ORATORIO study","volume":"96","author":"Zivadinov","year":"2021","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD013247.pub2-BIB0247|cit247","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1083\/jcb.121.5.1121","article-title":"Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes","volume":"121","author":"Bubien","year":"1993","journal-title":"Journal of Cell Biology"},{"issue":"1","key":"10.1002\/14651858.CD013247.pub2-BIB0248|cit248","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1212\/WNL.47.1.129","article-title":"Validation of the Functional Assessment of Multiple Sclerosis quality of life instrument","volume":"47","author":"Cella","year":"1996","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD013247.pub2-BIB0249|cit249","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nature Medicine"},{"issue":"22 Suppl 3","key":"10.1002\/14651858.CD013247.pub2-BIB0250|cit250","first-page":"13","article-title":"Pathogenesis of myelin\/oligodendrocyte damage in multiple sclerosis","volume":"68","author":"Dhib-Jalbut","year":"2007","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD013247.pub2-BIB0251|cit251","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis \u2013 a review","volume":"26","author":"Dobson","year":"2019","journal-title":"European Journal of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD013247.pub2-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pneurobio.2010.09.005","article-title":"Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis","volume":"93","author":"Dutta","year":"2011","journal-title":"Progress in Neurobiology"},{"key":"10.1002\/14651858.CD013247.pub2-BIB0253|cit253","unstructured":"FDA approves new drug to treat multiple sclerosis www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm549325.htm"},{"issue":"4","key":"10.1002\/14651858.CD013247.pub2-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/135245859900500410","article-title":"Recent developments in the assessment of quality of life in multiple sclerosis (MS)","volume":"5","author":"Fischer","year":"1999","journal-title":"Multiple Sclerosis"},{"issue":"001","key":"10.1002\/14651858.CD013247.pub2-BIB0255|cit255","first-page":"23","article-title":"Comparative efficacy of disease-modifying therapies for patients with relapsing remitting multiple sclerosis: systematic review and network meta-analysis","volume":"9","author":"Fogarty","year":"2017","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"10.1002\/14651858.CD013247.pub2-BIB0256|cit256","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"key":"10.1002\/14651858.CD013247.pub2-BIB0257|cit257","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021 Available from training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD013247.pub2-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.ncl.2016.06.016","article-title":"Epidemiology of multiple sclerosis","volume":"34","author":"Howard","year":"2016","journal-title":"Neurologic Clinics"},{"issue":"1","key":"10.1002\/14651858.CD013247.pub2-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cell.2018.08.011","article-title":"Memory B cells activate brain-homing, autoreactive CD4+ T cells in multiple sclerosis","volume":"175","author":"Jelcic","year":"2018","journal-title":"Cell"},{"issue":"5","key":"10.1002\/14651858.CD013247.pub2-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/S1474-4422(10)70064-8","article-title":"The changing demographic pattern of multiple sclerosis epidemiology","volume":"9","author":"Koch-Henriksen","year":"2010","journal-title":"Lancet Neurology"},{"issue":"310","key":"10.1002\/14651858.CD013247.pub2-BIB0261|cit261","doi-asserted-by":"crossref","first-page":"310ra166","DOI":"10.1126\/scitranslmed.aab4176","article-title":"Proinflammatory GM-CSF-producing B cells in multiple sclerosis and B cell depletion therapy","volume":"7","author":"Li","year":"2015","journal-title":"Science Translational Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013247.pub2-BIB0262|cit262","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","article-title":"Defining the clinical course of multiple sclerosis: the 2013 revisions","volume":"83","author":"Lublin","year":"2015","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD013247.pub2-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.msard.2018.12.040","article-title":"Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis","volume":"29","author":"McCool","year":"2019","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"1","key":"10.1002\/14651858.CD013247.pub2-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/ana.1032","article-title":"Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis","volume":"50","author":"McDonald","year":"2001","journal-title":"Annals of Neurology"},{"issue":"9","key":"10.1002\/14651858.CD013247.pub2-BIB0265|cit265","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1080\/14740338.2020.1807002","article-title":"Safety profile of ocrelizumab for the treatment of multiple sclerosis: a systematic review","volume":"19","author":"Ng","year":"2020","journal-title":"Expert Opinion On Drug Safety"},{"key":"10.1002\/14651858.CD013247.pub2-BIB0266|cit266","volume-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury \u2013 Multiple Sclerosis Agents","author":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","year":"2021"},{"issue":"2","key":"10.1002\/14651858.CD013247.pub2-BIB0267|cit267","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4049\/jimmunol.1400118","article-title":"Rituximab efficiently depletes increased CD20-expressing TcCells in multiple sclerosis patients","volume":"193","author":"Palanichamy","year":"2014","journal-title":"Journal of Immunology"},{"issue":"6","key":"10.1002\/14651858.CD013247.pub2-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \"McDonald Criteria\"","volume":"58","author":"Polman","year":"2005","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD013247.pub2-BIB0269|cit269","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD013247.pub2-BIB0270|cit270","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"key":"10.1002\/14651858.CD013247.pub2-BIB0271|cit271","unstructured":"Review Manager 5 (RevMan 5) The Nordic Cochrane Centre, The Cochrane Collaboration 2020"},{"issue":"5","key":"10.1002\/14651858.CD013247.pub2-BIB0272|cit272","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41582-019-0170-8","article-title":"Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis","volume":"15","author":"Rotstein","year":"2019","journal-title":"Nature Reviews Neurology"},{"issue":"1","key":"10.1002\/14651858.CD013247.pub2-BIB0273|cit273","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/1756285615601933","article-title":"The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects","volume":"9","author":"Sorensen","year":"2016","journal-title":"Therapeutic Advances in Neurological Disorders"},{"issue":"9","key":"10.1002\/14651858.CD013247.pub2-BIB0274|cit274","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s40263-018-0568-7","article-title":"Ocrelizumab: a review in multiple sclerosis","volume":"32","author":"Syed","year":"2018","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1002\/14651858.CD013247.pub2-BIB0275|cit275","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurology"},{"issue":"6","key":"10.1002\/14651858.CD013247.pub2-BIB0276|cit276","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40263-018-0530-8","article-title":"Disability outcome measures in phase III clinical trials in multiple sclerosis","volume":"32","author":"Uitdehaag","year":"2018","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1002\/14651858.CD013247.pub2-BIB0277|cit277","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/BF02260859","article-title":"A health-related quality of life measure for multiple sclerosis","volume":"4","author":"Vickrey","year":"1995","journal-title":"Quality of Life Research"},{"issue":"6","key":"10.1002\/14651858.CD013247.pub2-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item Short-Form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Sherbourne","year":"1992","journal-title":"Medical Care"},{"issue":"1","key":"10.1002\/14651858.CD013247.pub2-BIB0279|cit279","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013247","article-title":"Ocrelizumab for multiple sclerosis","author":"Lin","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T20:19:04Z","timestamp":1731961144000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013247.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":279,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013247.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]}}}